Sutro Biopharma Inc
STRO0.827USD
+0.017+2.11%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
69.77MMarket Cap
LossP/E TTM
More Details of Sutro Biopharma Inc Company
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Company Info
Ticker SymbolSTRO
Company nameSutro Biopharma Inc
IPO dateSep 27, 2018
CEOMs. Jane Chung
Number of employees310
Security typeOrdinary Share
Fiscal year-endSep 27
Address111 Oyster Point Blvd.
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94080
Phone16503928412
Websitehttps://www.sutrobio.com/
Ticker SymbolSTRO
IPO dateSep 27, 2018
CEOMs. Jane Chung
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairman of the Board
Independent Chairman of the Board
116.24K
--
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
98.31K
+39.76%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
53.69K
+3.08%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
22.46K
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Mr. Joseph M. Lobacki
Mr. Joseph M. Lobacki
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Panek
Mr. James P. (Jim) Panek
Independent Director
Independent Director
--
--
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
--
--
Ms. Emily White
Ms. Emily White
Executive Director - Investor Relations and Communications
Executive Director - Investor Relations and Communications
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairman of the Board
Independent Chairman of the Board
116.24K
--
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
98.31K
+39.76%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
53.69K
+3.08%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
22.46K
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
8.84%
BlackRock Institutional Trust Company, N.A.
6.59%
Kynam Capital Management LP
6.44%
Millennium Management LLC
5.59%
RA Capital Management, LP
5.25%
Other
67.30%
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
8.84%
BlackRock Institutional Trust Company, N.A.
6.59%
Kynam Capital Management LP
6.44%
Millennium Management LLC
5.59%
RA Capital Management, LP
5.25%
Other
67.30%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.69%
Investment Advisor/Hedge Fund
18.32%
Investment Advisor
17.28%
Venture Capital
8.09%
Corporation
3.22%
Research Firm
1.44%
Individual Investor
1.37%
Pension Fund
0.34%
Bank and Trust
0.11%
Other
20.12%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
291
67.18M
79.53%
-15.59M
2025Q1
295
63.49M
75.19%
-18.52M
2024Q4
299
65.68M
79.84%
-13.78M
2024Q3
295
64.44M
78.61%
-17.80M
2024Q2
286
64.98M
79.66%
-15.82M
2024Q1
291
55.64M
88.75%
-15.66M
2023Q4
302
58.38M
95.62%
-12.57M
2023Q3
306
61.36M
101.61%
-9.98M
2023Q2
312
60.26M
100.55%
-11.07M
2023Q1
320
58.55M
98.20%
-11.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Suvretta Capital Management, LLC
7.46M
8.84%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.57M
6.59%
-721.98K
-11.48%
Mar 31, 2025
Kynam Capital Management LP
5.44M
6.44%
+1.80M
+49.43%
Mar 31, 2025
Millennium Management LLC
4.72M
5.59%
+4.01M
+570.86%
Jun 27, 2025
RA Capital Management, LP
4.43M
5.25%
+4.43M
--
Mar 31, 2025
The Vanguard Group, Inc.
4.40M
5.2%
+186.74K
+4.44%
Mar 31, 2025
Acadian Asset Management LLC
3.13M
3.71%
+1.38M
+78.92%
Mar 31, 2025
Merck & Co Inc
2.72M
3.22%
--
--
Mar 31, 2025
Vestal Point Capital, LP
2.60M
3.08%
+30.00K
+1.17%
Mar 31, 2025
Eversept Partners, LP
2.29M
2.71%
+1.60M
+230.10%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Vanguard US Value Factor ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
iShares US Small-Cap Equity Factor ETF
0%
Global X Russell 2000 Covered Call ETF
0%
View more
Vanguard US Value Factor ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Micro-Cap ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares US Small-Cap Equity Factor ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
